Nothing Special   »   [go: up one dir, main page]

ECSP034874A - Benzoilsulfonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales - Google Patents

Benzoilsulfonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales

Info

Publication number
ECSP034874A
ECSP034874A EC2003004874A ECSP034874A ECSP034874A EC SP034874 A ECSP034874 A EC SP034874A EC 2003004874 A EC2003004874 A EC 2003004874A EC SP034874 A ECSP034874 A EC SP034874A EC SP034874 A ECSP034874 A EC SP034874A
Authority
EC
Ecuador
Prior art keywords
sulfonylbenzamidins
benzoilsulfonamids
antitumural
agents
antitumor
Prior art date
Application number
EC2003004874A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Ho-Shen Lin
Chuan Shih
Karen Lynn Lobb
Cora Sue Grossman
Thomas Hughes Corbett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP034874A publication Critical patent/ECSP034874A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invención proporciona compuestos antitumorales de la Fórmula (I) y métodos antitumorales.
EC2003004874A 2001-06-06 2003-12-02 Benzoilsulfonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales ECSP034874A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29635001P 2001-06-06 2001-06-06

Publications (1)

Publication Number Publication Date
ECSP034874A true ECSP034874A (es) 2004-01-28

Family

ID=23141662

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004874A ECSP034874A (es) 2001-06-06 2003-12-02 Benzoilsulfonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales

Country Status (36)

Country Link
US (1) US7183320B2 (es)
EP (1) EP1401806B1 (es)
JP (1) JP4167173B2 (es)
KR (1) KR100880760B1 (es)
CN (1) CN100475787C (es)
AR (1) AR036079A1 (es)
AT (1) ATE335722T1 (es)
AU (1) AU2002259204B2 (es)
BR (1) BR0210078A (es)
CA (1) CA2446719A1 (es)
CR (1) CR7182A (es)
CY (1) CY1105386T1 (es)
CZ (1) CZ20033296A3 (es)
DE (1) DE60213810T2 (es)
DK (1) DK1401806T3 (es)
EA (1) EA005810B1 (es)
EC (1) ECSP034874A (es)
EG (1) EG24356A (es)
ES (1) ES2269688T3 (es)
HK (1) HK1064360A1 (es)
HR (1) HRP20031000A2 (es)
HU (1) HUP0400114A3 (es)
IL (1) IL158985A0 (es)
MX (1) MXPA03011197A (es)
MY (1) MY136855A (es)
NO (1) NO20035366L (es)
NZ (1) NZ529098A (es)
PE (1) PE20030199A1 (es)
PL (1) PL367188A1 (es)
PT (1) PT1401806E (es)
SK (1) SK14642003A3 (es)
SV (1) SV2003001076A (es)
TW (1) TWI266761B (es)
UA (1) UA74889C2 (es)
WO (1) WO2002098848A1 (es)
ZA (1) ZA200308644B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565438B1 (en) * 2002-11-22 2007-10-17 Eli Lilly And Company Antitumor benzoylsulfonamides
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
EP1765778B1 (en) * 2004-05-26 2012-01-25 Abbott Laboratories N-sulfonylcarboximidamide apoptosis promoters
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
WO2006030941A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
ME01222B (me) * 2005-02-28 2013-06-20 Eisai R&D Man Co Ltd Nova kombinovana upotreba jedinjenja sulfonamida u liječenju kancera
EP1862179A4 (en) * 2005-02-28 2010-12-15 Eisai R&D Man Co Ltd NOVEL USE OF A SULFONAMIDE COMPOUND IN COMBINATION WITH AN ANGIOGENESIS INHIBITOR
PL2757099T3 (pl) 2005-05-12 2018-02-28 Abbvie Bahamas Limited Promotory apoptozy
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
US20100291592A1 (en) 2006-04-20 2010-11-18 Taro Semba Novel marker for sensitivity against sulfonamide compound
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CN101675033A (zh) * 2007-05-16 2010-03-17 霍夫曼-拉罗奇有限公司 芳基吡啶基磺酰胺衍生物，它们的制备和作为药剂的应用
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
DK2511264T3 (da) * 2009-01-19 2015-06-22 Abbvie Inc Apoptose-inducerende midler til behandling af cancer og immunsygdomme og autoimmune sygdomme
JP2012136435A (ja) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd 腫瘍組織の感受性を検査する方法
KR200457823Y1 (ko) * 2009-05-08 2012-01-05 황정용 쭈꾸미 포획용 어구
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CA3206963A1 (en) 2009-05-26 2010-12-02 Abbvie Ireland Unlimited Company (hetero)aryl substituted sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-oxy) benzamide compounds and their use as apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX2012011086A (es) * 2010-03-25 2013-03-21 Abbvie Inc Agentes inductores de apoptosis para el tratamiento de cancer y de enfermedades inmunitarias y autoinmunitarias.
US20120277210A1 (en) 2010-10-29 2012-11-01 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105712925B (zh) * 2014-12-05 2019-01-04 沈阳中化农药化工研发有限公司 一种取代的磺酰胺基(硫代)羰基化合物及其用途
EP3259250A1 (en) 2015-02-13 2017-12-27 Oxford Drug Design Limited Novel n-acyl-arylsulfonamide derivatives as aminoacyl-trna synthetase inhibitors
CN105753748B (zh) * 2016-02-15 2018-05-29 南京励合化学新材料有限公司 一种医药中间体磺酰类化合物的合成方法
GB201617064D0 (en) 2016-10-07 2016-11-23 Inhibox Limited And Latvian Institute Of Organic Synthesis The Compounds and their therapeutic use
US11479532B2 (en) * 2017-06-23 2022-10-25 University Of South Florida 5-aminolevulinate synthase inhibitors and methods of use thereof
KR20230127355A (ko) * 2017-12-29 2023-08-31 공윈 바이오팜 컴퍼니, 리미티드 (타이완) 벤젠술폰아미드 유도체 및 지질 래프트 조정 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157257A (en) 1976-10-01 1979-06-05 Utsunomiya University Benzenesulfonamide derivatives
US4433997A (en) * 1979-04-20 1984-02-28 Stauffer Chemical Co N-Acylsulfonamide herbicidal antidotes
US4347380A (en) * 1979-04-20 1982-08-31 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4266078A (en) * 1979-04-20 1981-05-05 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4495365A (en) * 1980-11-21 1985-01-22 Stauffer Chemical Co. N-Acylsulfonamide herbicidal antidotes
US5110830A (en) * 1984-06-27 1992-05-05 Eli Lilly And Company Benzenesulfonamides treatment of tumors susceptible to
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
JP2679498B2 (ja) * 1991-12-25 1997-11-19 王子製紙株式会社 感熱記録体
CA2110524A1 (en) 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
JPH0747772A (ja) * 1993-08-05 1995-02-21 New Oji Paper Co Ltd 感熱記録体
AU5772196A (en) 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
ES2193615T3 (es) 1995-10-25 2003-11-01 Senju Pharma Co .nhibidor de la angiogenesis.
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU2879300A (en) * 1999-02-12 2000-08-29 Cellpath, Inc. Methods for anti-tumor therapy
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis

Also Published As

Publication number Publication date
DE60213810T2 (de) 2007-02-01
HUP0400114A3 (en) 2007-05-02
BR0210078A (pt) 2004-06-22
CN100475787C (zh) 2009-04-08
MXPA03011197A (es) 2004-02-26
PT1401806E (pt) 2006-11-30
CY1105386T1 (el) 2010-04-28
EP1401806A1 (en) 2004-03-31
CA2446719A1 (en) 2002-12-12
ES2269688T3 (es) 2007-04-01
SV2003001076A (es) 2003-07-29
AU2002259204B2 (en) 2008-01-17
ZA200308644B (en) 2005-02-07
DE60213810D1 (de) 2006-09-21
TWI266761B (en) 2006-11-21
EP1401806B1 (en) 2006-08-09
AR036079A1 (es) 2004-08-11
US20040157741A1 (en) 2004-08-12
WO2002098848A1 (en) 2002-12-12
CN1514824A (zh) 2004-07-21
ATE335722T1 (de) 2006-09-15
EA200400006A1 (ru) 2004-06-24
MY136855A (en) 2008-11-28
HUP0400114A2 (hu) 2005-04-28
CR7182A (es) 2004-06-08
EA005810B1 (ru) 2005-06-30
NO20035366L (no) 2004-02-06
JP4167173B2 (ja) 2008-10-15
UA74889C2 (en) 2006-02-15
IL158985A0 (en) 2004-05-12
KR20040007656A (ko) 2004-01-24
DK1401806T3 (da) 2006-11-27
PE20030199A1 (es) 2003-03-12
JP2004530709A (ja) 2004-10-07
CZ20033296A3 (cs) 2004-04-14
SK14642003A3 (sk) 2004-12-01
PL367188A1 (en) 2005-02-21
NZ529098A (en) 2005-08-26
EG24356A (en) 2009-03-04
NO20035366D0 (no) 2003-12-02
HK1064360A1 (en) 2005-01-28
US7183320B2 (en) 2007-02-27
KR100880760B1 (ko) 2009-02-02
HRP20031000A2 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
ECSP034874A (es) Benzoilsulfonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
DE60230890D1 (de) Indolizine als kinaseproteinhemmer
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
DE60314623D1 (de) Substituierte pyrazolopyrimidine
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
ECSP045255A (es) Cumarinas utiles como biomarcadores
ATE375978T1 (de) Benzoylsulfonamide als antitumor-mittel
PT1473036E (pt) Solvato de hemitartarato de zolpidem
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
SE0103710D0 (sv) Compounds
MXPA04003755A (es) Endoprotesis vasculares.
DOP2005000010A (es) Inhibidores de quinasa
BR0115139A (pt) Compostos bis-heterocìclicos com atividade antitumor e quimiossensibilizante
ATE287403T1 (de) 6-phenylbenzonaphthyidine
TW200605885A (en) Multicyclic lonidamine analogs
BRPI0415038A (pt) derivados de imidazo (4,5-b) piridina como inibidores sem ser da sintase que podem ser induzidos
DE60304360D1 (de) N-aryl-2-oxazolidinone und deren derivate
DE50207869D1 (de) Metallorganisches antitumormittel
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
CY1110139T1 (el) Γλυκοπεπτιδικα αντιβιοτικα
GB0205327D0 (en) compounds
ATE364037T1 (de) Tryptasehemmer